By Denny Jacob

Regeneron Pharmaceuticals posted better-than-expected revenue and adjusted earnings per-share in its latest quarter, benefiting in part from higher sales for certain products in its portfolio and collaborative efforts.

The biotechnology company logged net income of $1.39 billion, or $12.81 a share, for the second quarter, down from $1.43 billion, or $12.41 a share, in the prior-year period.

Stripping out certain one-time items, earnings came in at $12.89 a share. Analysts polled by FactSet expected $8.43 a share.

Revenue edged up to $3.68 billion from $3.55 billion. Analysts polled by FactSet expected $3.29 billion.

Chief Executive Leonard Schleifer said the quarter was marked by growth in U.S. sales of EYLEA HD and global sales of Dupixent and Libtayo.

Sales of EYLEA HD rose to $393 million from $304 million a year earlier thanks to increased demand. EYLEA sales, meanwhile, declined to $754 million from $1.23 billion, which the company attributed to lower sales volume as a result of continued competitive pressures and the continued transition of patients to EYLEA HD, among other factors.

Total sales of EYLEA HD and EYLEA in the U.S. declined to $1.15 billion from $1.54 billion.

Other products in its portfolio, including Libtayo and Praluent, increased in sales from a year earlier. Total product sales declined to $1.63 billion from $1.92 billion.

Total revenue also benefited from higher collaboration revenue from work with Sanofi and Bayer.

Write to Denny Jacob at denny.jacob@wsj.com

(END) Dow Jones Newswires

August 01, 2025 07:18 ET (11:18 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.